查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2014923

肝病治療市場：2026-2030年全球市場預測（依疾病、治療方法、給藥途徑、藥物類別、最終用戶和分銷管道分類）

Liver Diseases Therapeutics Market by Disease Type, Therapy Type, Route Of Administration, Drug Class, End User, Distribution Channel - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年肝病治療市場價值為 187.6 億美元，預計到 2025 年將成長至 202.6 億美元，複合年成長率為 8.13%，到 2030 年將達到 300 億美元。

主要市場統計數據
基準年 2024 187.6億美元
預計年份：2025年 202.6億美元
預測年份：2030年 300億美元
複合年成長率 (%) 8.13%

對目前肝病治療策略的現狀和未來可能性進行詳細考察，以應對肝病帶來的挑戰。

隨著肝病盛行率和複雜性的不斷增加，迫切需要能夠有效應對各種急慢性肝病的創新治療策略。儘管傳統療法長期以來依賴抗病毒藥物和支持性治療，但近年來，隨著對纖維化機制、免疫調節和細胞再生認知的不斷深入，肝病治療領域正在發生顯著變化。本文探討了跨學科研究、先進的生物技術平台和以患者為中心的治療模式如何融合，進而重塑肝病治療。

近期科學突破和以病人為中心的創新如何重新定義肝病治療的方法和結果？

過去十年，科學突破徹底改變了我們對肝臟疾病的理解和治療。基因療法的創新為糾正潛在的遺傳易感性提供了可能，而細胞療法和再生醫學的進步則為恢復肝功能提供了新的策略。同時，微生物組調節療法的引入，透過利用腸道-肝軸的相互作用來減少發炎和纖維化，從而重新定義了肝臟疾病的治療模式。

評估 2025 年美國關稅措施對肝病治療藥物的研發、供應鏈和取得的廣泛影響。

美國將於2025年實施關稅，將為全球肝病治療供應鏈帶來新的複雜性。從海外採購原料（包括基因和細胞療法所需的特殊生物成分和試劑）的成本壓力日益增加。隨著製造成本的上升，相關人員面臨著如何在不犧牲品質或可及性的前提下維持價格競爭力的挑戰。

透過對疾病類型、治療方法、給藥途徑、藥物類別、使用環境和分銷管道進行多方面細分，揭示關鍵見解。

精準了解患者亞群對於制定個人化的肝病治療性介入至關重要。疾病類型細分涵蓋了從酒精性肝病到慢性病毒感染疾病（如乙型和丙型肝炎）的全部範圍，以及肝癌亞型（如肝細胞癌和膽管​​癌）和日益成長的非酒精性脂肪性肝病。每一類疾病都有其獨特的病理學機轉和臨床管理考量。

檢驗美洲、歐洲、中東和非洲以及亞太地區肝病治療創新、取得和傳播的區域趨勢和具體影響因素。

區域趨勢對肝病治療方法的引入、發展和可近性有顯著影響。在美洲，健全的法規結構和完善的臨床試驗網路正在加速先進生技藥品和基因療法的引入。醫療保健系統日益注重以價值為導向的醫療服務，從而推動了對那些與現有標準療法相比能夠展現出明顯臨床和經濟效益的治療方法的需求。

透過研究和合作，我們概述了在全球肝病治療領域推動創新、夥伴關係和策略成長的最具影響力的組織。

肝病治療市場由一群主要企業主導，這些企業透過廣泛的研發管線、策略夥伴關係和有針對性的收購來推動創新。成熟的製藥公司繼續利用其全球研發能力推進大規模臨床項目，而新興生物技術公司則專注於高影響力細分領域，例如遺傳代謝疾病的基因矯正和肝癌的個人化免疫療法。

肝病治療藥物研發與交付領域的產業領導者面臨的策略挑戰：抓住新機會、降低風險、促進永續成長。

產業領導者必須採取果斷行動，最大限度地掌握肝病治療領域的新興機會。首先，投資靈活的生產平台，能夠減少供應鏈中斷，並提高應對力關稅成本壓力的能力，從而確保患者獲得不間斷的治療。各機構應探索夥伴關係，利用風險共擔機制進行細胞和基因療法的共同研發，在降低成本的同時加速臨床開發進程。

本書匯集了關鍵亮點和策略考量，闡明了創新治療方法、協作方法和政策考量在推進肝病治療中的關鍵作用。

本執行摘要整合了定義肝病治療現狀及未來的關鍵趨勢、關稅的影響、細微的市場區隔差異、區域促進因素以及主要組織策略。先進的生技藥品平台、基因編輯技術和以患者為中心的治療模式的融合，正在重塑從病毒性肝炎到複雜肝細胞癌等多種疾病的治療前景。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肝病治療市場：依疾病類型分類

  • 酒精性肝臟疾病
  • B型肝炎
  • C型肝炎
  • 肝癌
    • 膽管癌
    • 肝細胞癌
  • 非酒精性肝臟疾病

第9章 肝病治療市場：依治療方法

  • 生物免疫療法
  • 細胞療法和再生醫學
  • 基因治療
  • 微生物組調節療法
  • 小分子藥物

第10章 肝病治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第11章 肝病治療市場：依藥物類別分類

  • 抗纖維化藥物
    • Pirfenidone
    • 辛妥珠單抗
  • 抗病毒藥物
    • 干擾素
    • NS5A抑制劑
    • NS5B聚合酵素抑制劑
    • 核苷酸/核苷類似物
    • 蛋白酶抑制劑
  • 化療藥物
  • 皮質類固醇
  • 免疫抑制劑
  • 單株抗體

第12章 肝病治療市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第13章 肝病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 肝病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 肝病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 肝病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國肝病治療市場

第18章：中國肝病治療市場

第19章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genfit SA
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Intercept Pharmaceuticals, Inc.（Alfasigma SpA）
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-437A5D08AE2A

The Liver Diseases Therapeutics Market was valued at USD 18.76 billion in 2024 and is projected to grow to USD 20.26 billion in 2025, with a CAGR of 8.13%, reaching USD 30.00 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 18.76 billion
Estimated Year [2025] USD 20.26 billion
Forecast Year [2030] USD 30.00 billion
CAGR (%) 8.13%

An In-Depth Exploration of the Current State and Future Potential in Therapeutic Strategies for Addressing Liver Disease Challenges

The escalating prevalence and complexity of liver diseases present an urgent imperative for innovative therapeutic strategies that can effectively address the spectrum of chronic and acute hepatic conditions. While traditional approaches have long relied on antiviral agents and supportive care, recent years have witnessed a profound shift driven by deeper insights into fibrotic mechanisms, immune modulation, and cellular regeneration. This introduction explores how multidisciplinary research, advanced biotechnology platforms, and patient-centered frameworks are converging to reshape the therapeutic landscape.

Throughout this report, attention is devoted to understanding how novel platforms-ranging from next-generation biologic immunotherapies to the precision of gene editing-are targeting pathophysiological pathways with unprecedented specificity. As the pipeline expands, comprehensive analyses will examine factors such as the evolving regulatory environment, supply chain resilience in light of new tariff policies, and synergies between established pharmaceutical players and emerging biotech innovators.

By presenting an integrated overview of strategic dynamics and emerging opportunities, this section sets the stage for a deeper exploration of transformative shifts, tariff implications, segmentation insights, and regional drivers that collectively inform strategic decision-making in the field of liver disease therapeutics.

How Recent Scientific Breakthroughs Coupled with Patient-Centric Innovations Are Redefining Therapeutic Approaches and Outcomes in Liver Disease Care

Over the past decade, scientific breakthroughs have catalyzed transformative shifts in how liver diseases are understood and managed. Innovations in gene therapy are unlocking the potential to correct underlying genetic predispositions, while advancements in cell-based and regenerative therapies are offering strategies to restore hepatic function. Concurrently, the introduction of microbiome-modulating therapies is redefining paradigms by harnessing gut-liver axis communications to attenuate inflammation and fibrosis.

In addition to technological leaps, patient-centric approaches are gaining prominence. Personalized immunotherapeutic regimens, informed by individual biomarker profiles, are enhancing efficacy and reducing adverse events. Furthermore, strategic alliances between pharmaceutical companies and academic research centers are accelerating translational efforts, resulting in streamlined clinical development pathways and more robust evidence generation.

As a result of these converging forces, liver disease therapeutics are transitioning from reactive symptom management toward proactive disease modification and potential reversal of hepatic damage. This section examines the catalysts driving this evolution, including shifts in regulatory expectations, expanded access programs, and the rising importance of real-world evidence in shaping therapeutic value propositions.

Assessing the Far-Reaching Consequences of the 2025 United States Tariff Measures on the Development, Supply Chains, and Accessibility of Liver Disease Treatments

The introduction of United States tariff measures in 2025 has introduced new complexities into the global supply chains for therapeutic agents targeting liver conditions. Raw materials sourced from overseas, including specialized biologic components and reagents for gene and cell therapies, have experienced increased cost pressures. As manufacturing expenses rise, stakeholders face challenges in maintaining competitive pricing structures without compromising quality or accessibility.

Moreover, these tariffs have prompted companies to reassess their sourcing strategies, with some opting to diversify suppliers or establish local production capabilities. Such shifts carry implications for production timelines, regulatory compliance, and inventory management. In parallel, research collaborations that depend on cross-border exchanges of proprietary materials and technologies are navigating a more intricate tariff landscape that demands enhanced logistical coordination.

Despite these headwinds, the tariff environment has also spurred greater investment in domestic manufacturing infrastructure and encouraged the exploration of alternative raw-material platforms. By evaluating the cumulative impact of these measures, industry leaders can develop resilient strategies that safeguard continuity of supply, optimize cost structures, and ensure ongoing patient access to critical liver disease therapies.

Unveiling Critical Insights from Multi-Dimensional Segmentation Across Disease Types, Therapeutic Modalities, Administration Routes, Drug Classes, User Settings, and Distribution Channels

A nuanced understanding of patient subpopulations is foundational to tailoring therapeutic interventions for liver diseases. Segmentation based on disease type captures the full spectrum from Alcoholic Liver Disease to chronic viral infections such as Hepatitis B and Hepatitis C, as well as hepatocellular and cholangiocarcinoma subtypes of liver cancer and the increasingly prevalent Non-Alcoholic Liver Disease. Each of these categories presents unique pathophysiological mechanisms and clinical management considerations.

Equally critical is analyzing the therapeutic modalities under investigation. Biologic immunotherapies are leveraging checkpoint inhibition and cytokine modulation, while cell-based and regenerative approaches seek to replace or repair damaged hepatic tissue. Gene therapies are poised to address inherited metabolic disorders, and microbiome-modulating interventions aim to restore gut-liver axis equilibrium. Meanwhile, the continued refinement of small-molecule compounds ensures a diverse arsenal against fibrotic and inflammatory pathways.

Routes of administration influence both patient adherence and pharmacokinetic profiles, with intravenous infusions facilitating high-dose or acute interventions, oral formulations providing convenience for chronic regimens, and subcutaneous injections offering a middle ground between efficacy and ease of use. Alongside these considerations, drug classes such as antifibrotic agents-encompassing molecules like pirfenidone and simtuzumab-and a range of antiviral compounds, including interferons and NS5A inhibitors, each play distinct roles in interrupting disease progression.

Finally, understanding the contexts in which therapies are delivered is essential. End users span from specialized clinics to home care settings and hospital environments, necessitating flexible treatment protocols and support infrastructures. Distribution channels, whether via hospital pharmacies, online dispensaries, or retail outlets, further shape access dynamics and patient experiences.

Examining Regional Dynamics and Unique Drivers Across the Americas, Europe Middle East & Africa, and Asia-Pacific That Influence Therapeutic Innovation, Access, and Adoption in Liver Disease Care

Regional dynamics exert a powerful influence on the adoption, development, and accessibility of liver disease therapies. In the Americas, strong regulatory frameworks and established clinical trial networks have accelerated the introduction of advanced biologics and gene therapies. Healthcare systems are increasingly focused on value-based care initiatives, driving demand for treatments that can demonstrate clear clinical and economic benefits over existing standards.

Europe, the Middle East, and Africa present a diverse landscape shaped by varying healthcare infrastructures and policy environments. Within this region, collaborative consortia have facilitated cross-border clinical studies, while multinational reimbursement pathways continue to evolve. Emerging economies are investing in expanded diagnostic and treatment capacities, creating new opportunities for therapies targeting both viral hepatitis and non-alcoholic steatohepatitis.

In Asia-Pacific, robust government support for research and development, combined with high prevalence rates of both viral and metabolic liver diseases, has cultivated a fertile environment for innovation. Local biotech enterprises are partnering with global pharmaceutical leaders to co-develop novel interventions, and patient access programs are adapting to the unique socioeconomic conditions across the region.

Together, these regional insights underscore the importance of tailored strategies that align regulatory, economic, and healthcare delivery considerations with the specific needs and drivers of each market.

Profiling the Most Influential Organizations Driving Innovation, Partnerships, and Strategic Growth in the Global Liver Disease Therapeutics Arena Through Research and Collaborations

The liver disease therapeutics landscape is shaped by a constellation of leading companies that drive innovation through expansive research pipelines, strategic partnerships, and targeted acquisitions. Established pharmaceutical entities continue to leverage their global development capabilities to advance large-scale clinical programs, while emerging biotechs are focusing on high-impact niches such as gene correction for inherited metabolic disorders and personalized immunotherapies for liver cancer.

Collaborative networks between academic institutions and industry players are increasingly prolific, enabling the rapid translation of preclinical discoveries into early-phase clinical trials. In parallel, alliances with contract manufacturing organizations are enhancing production scalability for complex biologics and cell therapies. The pursuit of orphan drug designations and accelerated approval pathways further illustrates how companies are navigating regulatory landscapes to bring breakthrough treatments to patients more swiftly.

Innovation is complemented by strategic investments in advanced manufacturing technologies, including closed-system bioreactors and automated cell processing, which collectively reduce production bottlenecks and improve batch consistency. Concurrently, players across the spectrum are exploring digital health integrations-from remote patient monitoring to AI-driven biomarker analysis-that have the potential to refine clinical development and broaden access.

Through a combination of in-house research excellence, external collaborations, and forward-looking technology adoption, these key companies are at the forefront of transforming liver disease treatment paradigms.

Strategic Imperatives for Industry Leaders to Capitalize on Emerging Opportunities, Mitigate Risks, and Foster Sustainable Growth in Liver Disease Therapeutic Development and Delivery

Industry leaders must act decisively to capitalize on emerging opportunities within liver disease therapeutics. First, investing in flexible manufacturing platforms will mitigate supply chain disruptions and enhance responsiveness to tariff-induced cost pressures, thereby safeguarding uninterrupted patient access. Organizations should evaluate partnerships that enable co-development of cell and gene therapies with shared risk models to accelerate clinical advancement while controlling expenses.

Second, adopting a patient-centric development framework will strengthen real-world evidence generation, optimize trial design, and improve adherence. Tailoring protocols to accommodate home care administration and digital health support can differentiate offerings and align with evolving care delivery trends. In parallel, leveraging biomarkers to stratify patient populations will increase the probability of clinical success and support value-based pricing discussions.

Third, proactive engagement with regulatory agencies across key regions will facilitate alignment on accelerated approval pathways and post-market surveillance requirements. Companies should establish cross-functional regulatory task forces that integrate global policy insights, ensuring that development strategies are robust and adaptable.

By executing on these strategic imperatives, industry leaders can drive sustainable growth, enhance therapeutic impact, and maintain a competitive advantage in the rapidly evolving field of liver disease care.

The insights presented in this report are built upon a rigorous, multi-layered research methodology designed to ensure accuracy, relevance, and comprehensive coverage of the liver disease therapeutics landscape. Primary research forms the backbone of our analysis, incorporating in-depth interviews with key opinion leaders, clinical investigators, regulatory specialists, and senior executives within pharmaceutical and biotech companies.

Complementing these qualitative insights, secondary research draws from peer-reviewed journals, clinical trial registries, patent filings, and regulatory documents to validate pipeline developments and technology trends. Data from publicly available corporate reports, scientific conferences, and institutional repositories further enrich the contextual understanding of competitive dynamics.

Analytical frameworks, including SWOT assessments and PESTEL evaluations, have been applied to interpret strategic positioning, innovation drivers, and external influences such as tariff policies. Triangulation of qualitative and quantitative data ensures that findings are cross-verified and free from bias.

Finally, ongoing validation through expert workshops and scenario analyses enhances the robustness of conclusions and recommendations, providing stakeholders with a dependable foundation for strategic planning and investment decisions.

Synthesis of Key Findings and Strategic Reflections That Highlight the Pivotal Role of Innovative Therapies, Collaborative Efforts, and Policy Considerations in Advancing Liver Disease Treatment

This executive summary has synthesized the critical trends, tariff implications, segmentation nuances, regional drivers, and key organizational strategies that define the current and future state of liver disease therapeutics. The convergence of advanced biologic platforms, gene editing technologies, and patient-centric delivery models is reshaping treatment possibilities for conditions ranging from viral hepatitis to complex hepatocellular carcinomas.

By examining the cumulative impact of United States tariff measures, this report underscores the importance of resilient supply chain strategies and diversified manufacturing approaches. Segmentation analyses reveal distinct treatment pathways tailored to varied disease subtypes, therapeutic mechanisms, and delivery environments, while regional insights highlight the need for market-specific strategies informed by local healthcare infrastructures and regulatory landscapes.

Strategic recommendations emphasize the value of collaborative development models, patient-data integration, and proactive regulatory engagement. Together, these elements form a cohesive roadmap for stakeholders to navigate challenges, seize opportunities, and drive continued innovation in liver disease care.

In conclusion, the accelerated pace of scientific and policy evolution calls for decisive, informed action to translate research breakthroughs into tangible clinical benefits and deliver sustainable value to patients and healthcare systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Diseases Therapeutics Market, by Disease Type

  • 8.1. Alcoholic Liver Disease
  • 8.2. Hepatitis B
  • 8.3. Hepatitis C
  • 8.4. Liver Cancer
    • 8.4.1. Cholangiocarcinoma
    • 8.4.2. Hepatocellular Carcinoma
  • 8.5. Non Alcoholic Lever Disease

9. Liver Diseases Therapeutics Market, by Therapy Type

  • 9.1. Biologic Immunotherapies
  • 9.2. Cell-Based & Regenerative Therapy
  • 9.3. Gene Therapy
  • 9.4. Microbiome-Modulating Therapies
  • 9.5. Small-Molecule Drugs

10. Liver Diseases Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Liver Diseases Therapeutics Market, by Drug Class

  • 11.1. Antifibrotic
    • 11.1.1. Pirfenidone
    • 11.1.2. Simtuzumab
  • 11.2. Antivirals
    • 11.2.1. Interferons
    • 11.2.2. NS5A Inhibitors
    • 11.2.3. NS5B Polymerase Inhibitors
    • 11.2.4. Nucleotide/Nucleoside Analogues
    • 11.2.5. Protease Inhibitors
  • 11.3. Chemotherapeutic
  • 11.4. Corticosteroids
  • 11.5. Immunosuppressants
  • 11.6. Monoclonal Antibody

12. Liver Diseases Therapeutics Market, by End User

  • 12.1. Clinic
  • 12.2. Home Care Settings
  • 12.3. Hospital

13. Liver Diseases Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Liver Diseases Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Liver Diseases Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Liver Diseases Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Liver Diseases Therapeutics Market

18. China Liver Diseases Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. AbbVie Inc.
  • 19.6. Alnylam Pharmaceuticals, Inc.
  • 19.7. Astellas Pharma Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. C. H. Boehringer Sohn AG & Co. KG
  • 19.11. Eli Lilly and Company
  • 19.12. F. Hoffmann-La Roche Ltd.
  • 19.13. Genfit S.A.
  • 19.14. Gilead Sciences, Inc.
  • 19.15. GlaxoSmithKline plc
  • 19.16. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • 19.17. Johnson & Johnson Services Inc.
  • 19.18. Merck & Co., Inc.
  • 19.19. Moderna, Inc.
  • 19.20. Novartis AG
  • 19.21. Pfizer Inc.
  • 19.22. Sanofi SA
  • 19.23. Takeda Pharmaceutical Company Limited
  • 19.24. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 14. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 101. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 105. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 106. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 108. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 111. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 114. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 115. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 117. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 121. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 122. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 127. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 131. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 132. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 137. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 141. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 142. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 165. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 167. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 171. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 172. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 175. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 177. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 181. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 182. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 196. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 198. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 202. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 203. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 206. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 208. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 212. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 213. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 226. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 228. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 232. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 233. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 236. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 238. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 242. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 243. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 244. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 245. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 246. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 248. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 251. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 252. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 253. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 256. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 257. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 259. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 263. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 264. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 267. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 269. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 272. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 273. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 274. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 275. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)